Improvements in psoriasis within different body regions vary over time following treatment with ixekizumab
- 29 September 2017
- journal article
- research article
- Published by Taylor & Francis Ltd in Journal of Dermatological Treatment
- Vol. 29 (3), 220-229
- https://doi.org/10.1080/09546634.2017.1365114
Abstract
Background: Ixekizumab is a high-affinity monoclonal antibody that selectively targets interleukin-17 A. Objective: Examine the efficacy of ixekizumab in clearing psoriasis within different body regions. Methods: Data from 3 placebo- (PBO) or PBO- and etanercept (ETN)-controlled trials were integrated. Patients with moderate-to-severe psoriasis were randomized to 12 weeks of PBO (UNCOVER-1, -2, -3, N = 792; UNCOVER-2, -3, N = 361), 50 mg ETN twice weekly (N = 740), or 80 mg ixekizumab every 2 (IXE Q2W; N = 1169; N = 736) or 4 weeks (IXE Q4W; N = 1165; N = 733) after a 160-mg starting dose. Results: Mean percent improvements in regional Psoriasis Area and Severity Index (PASI) were noted at Week 1 and increased through Week 12 in the IXE Q2W (approved dosing regimen) group for each body region. Week 12 improvements were 91.4% (head/neck); 92.8% (trunk); 89.9% (arms); and 88.7% (legs) (all regions p < .001 vs. PBO). Mean regional PASI improvements at Week 12 were ≥84.2% for ixekizumab versus ≤70.9% for ETN in all regions (p < .001). Scaling and thickness reduced faster than erythema. Conclusions: Within 12 weeks of ixekizumab treatment, all signs of psoriasis across all body regions reached clinically meaningful improvements, with the head/neck and trunk responding quicker than psoriasis of the arms and legs, especially with reduced scaling and thickness.Keywords
Funding Information
- Eli Lilly and Company
This publication has 18 references indexed in Scilit:
- A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasisJournal of the American Academy of Dermatology, 2014
- Pattern of response in patients with moderate-to-severe psoriasis treated with etanerceptBritish Journal of Dermatology, 2014
- Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque PsoriasisThe New England Journal of Medicine, 2012
- The Cutaneous Vascular System in Chronic Skin InflammationJournal of Investigative Dermatology Symposium Proceedings, 2011
- British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009British Journal of Dermatology, 2009
- Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologicsJournal of the American Academy of Dermatology, 2008
- Psoriasis assessment tools in clinical trialsAnnals Of The Rheumatic Diseases, 2005
- Rethinking the Psoriasis Area and Severity Index: the impact of area should be increasedBritish Journal of Dermatology, 2004
- The Burden of Psoriasis Is Not Determined by Disease Severity OnlyJournal of Investigative Dermatology Symposium Proceedings, 2004
- Severe Psoriasis – Oral Therapy with a New RetinoidDermatology, 1978